Alzheimer's Disease

Alzheimer's disease is the most common form of dementia — a progressive, irreversible neurodegenerative disorder characterised by the gradual loss of memory, cognitive function, language, judgement and the ability to perform everyday activities. It is the leading cause of dementia worldwide — accounting for approximately 60–70% of all dementia cases — and affects more than 55 million people globally, with a new case diagnosed approximately every 3 seconds. Named after the German psychiatrist and neuropathologist Dr. Alois Alzheimer — who first described the condition in 1906 following his examination of the brain of a patient named Auguste Deter — Alzheimer's disease is one of the greatest medical, scientific and social challenges of the 21st century.

Alzheimer's disease is not simply a consequence of normal ageing — it is a specific disease with identifiable pathological hallmarks — the accumulation of amyloid-β plaques between neurons and the formation of neurofibrillary tangles of hyperphosphorylated tau protein inside neurons — that disrupt neuronal function and ultimately cause neuronal death. The disease progresses relentlessly — from early subtle memory impairment through moderate cognitive decline to severe dementia — leaving patients entirely dependent on others for all aspects of daily care.

Despite decades of intensive research and billions of dollars of investment, effective disease-modifying treatments for Alzheimer's disease have only very recently begun to emerge — with the approval of two anti-amyloid antibodies (lecanemab and donanemab) in 2023–2024 representing the first treatments shown to meaningfully slow the progression of Alzheimer's disease. Understanding the molecular mechanisms of Alzheimer's disease — including the roles of amyloid-β, tau, neuroinflammation, oxidative stress, iron dysregulation and ferroptosis — remains one of the most active and important areas in all of biomedical research.

History

Discovery

Alzheimer's disease was first described by Dr. Alois Alzheimer — a German psychiatrist and neuropathologist — in 1906. In 1901, Dr. Alzheimer began studying a 51-year-old patient named Auguste Deter — who presented with unusual symptoms including severe memory loss, language difficulties, disorientation, hallucinations and disturbed behaviour — clearly distinct from the ordinary forgetfulness of old age.

Following Auguste Deter's death in 1906, Dr. Alzheimer examined her brain — using novel silver staining techniques — and identified two characteristic pathological findings: abnormal deposits between neurons (later identified as amyloid plaques) and abnormal fibres within neurons (later identified as neurofibrillary tangles). He presented his findings at a meeting of German psychiatrists in 1906 — describing "a peculiar severe disease process of the cerebral cortex" — the first scientific description of what would later bear his name.

In 1910, the psychiatrist Emil Kraepelin — a colleague and mentor of Dr. Alzheimer — named the condition Alzheimer's disease in the eighth edition of his landmark textbook of psychiatry — cementing the eponym that has persisted to the present day.

Modern Era

For much of the 20th century, Alzheimer's disease was considered a rare condition — known as presenile dementia — affecting only people under the age of 65. The far more common dementia of old age — senile dementia — was considered a normal part of ageing. It was not until the 1970s and 1980s that neuropathologists and neurologists — particularly through the work of Robert Katzman — established that presenile Alzheimer's disease and senile dementia were the same condition — distinguished only by the age of onset — and that what had been dismissed as normal ageing was in fact a devastating disease.

This recognition transformed the medical and public response to Alzheimer's disease — leading to the establishment of the Alzheimer's Association in 1980, a massive expansion of research funding and the emergence of Alzheimer's disease as one of the defining medical challenges of the late 20th and 21st centuries.

Epidemiology

Alzheimer's disease affects more than 55 million people worldwide — a number projected to reach 139 million by 2050 as the global population ages
It is the 7th leading cause of death globally
Approximately 10 million new cases are diagnosed worldwide every year
The risk of Alzheimer's disease doubles approximately every 5 years after the age of 65 — affecting approximately 3% of people aged 65–74, 17% of people aged 75–84 and 32% of people aged 85 and older
Women are disproportionately affected — accounting for approximately 65% of all Alzheimer's patients — partly due to their longer life expectancy and partly due to biological factors including hormonal differences
In India, approximately 4 million people are estimated to have Alzheimer's disease — a number expected to grow substantially as India's population ages

Pathology

The two defining pathological hallmarks of Alzheimer's disease — amyloid plaques and neurofibrillary tangles — were identified by Dr. Alois Alzheimer in 1906 and have remained central to understanding the disease for more than a century:

Amyloid-β Plaques

Amyloid-β (Aβ) plaques — also called senile plaques or neuritic plaques — are abnormal extracellular deposits of amyloid-β protein — a small peptide of 36–43 amino acids generated by the sequential cleavage of the amyloid precursor protein (APP) by the enzymes beta-secretase (BACE1) and gamma-secretase.

Under normal circumstances, amyloid-β is produced continuously in the brain and cleared efficiently — maintaining a dynamic equilibrium between production and clearance. In Alzheimer's disease, this equilibrium is disrupted — either through increased production of amyloid-β (as in familial Alzheimer's disease caused by APP or presenilin mutations) or through reduced clearance — leading to the progressive accumulation of amyloid-β in the brain.

Amyloid-β monomers aggregate progressively — first into soluble oligomers (which are now believed to be the most toxic form) — then into protofibrils and finally into the insoluble fibrillar amyloid plaques that can be visualised post-mortem under the microscope and in vivo by amyloid PET imaging. The amyloid plaques are surrounded by dystrophic neurites (damaged neuronal processes), reactive astrocytes and activated microglia — creating a local inflammatory environment that contributes to neuronal injury.

Neurofibrillary Tangles

Neurofibrillary tangles (NFTs) are abnormal intracellular inclusions found within neurons — composed of paired helical filaments of hyperphosphorylated tau protein. Tau is a microtubule-associated protein that normally stabilises the microtubule network of neurons — maintaining the structural integrity of axons and facilitating axonal transport. In Alzheimer's disease, tau is abnormally phosphorylated at multiple sites — causing it to detach from microtubules, aggregate into paired helical filaments and accumulate as insoluble neurofibrillary tangles inside neurons.

The formation of neurofibrillary tangles is directly associated with neuronal dysfunction and death — and the spread of tau pathology through the brain — following the stereotypical Braak staging pattern — correlates more closely with clinical symptom severity and cognitive decline than the distribution of amyloid plaques.

Neuroinflammation

Neuroinflammation — driven by the activation of microglia and astrocytes in response to amyloid plaques, damaged neurons and other pathological stimuli — is increasingly recognised as a major driver of Alzheimer's disease progression. Activated microglia surround amyloid plaques — attempting to clear them through phagocytosis — but in chronic activation produce a toxic inflammatory environment characterised by the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reactive oxygen species and other neurotoxic mediators.

Genetic risk variants — particularly variants in the microglial genes TREM2, CD33 and BIN1 — are among the most significant genetic risk factors for late-onset Alzheimer's disease — establishing neuroinflammation as a genetically validated driver of disease.

Neuronal Loss and Synaptic Dysfunction

Alzheimer's disease is characterised by progressive neuronal loss — particularly in the hippocampus (the brain's memory centre), the entorhinal cortex and — in later stages — throughout the neocortex. Synaptic loss — the loss of the connections between neurons — precedes and predicts neuronal death — and is the pathological change most closely correlated with cognitive decline in Alzheimer's disease.

Oxidative Stress and Iron Dysregulation

Oxidative stress — the accumulation of reactive oxygen species — and iron dysregulation — the accumulation of iron in amyloid plaques and neurofibrillary tangles — contribute significantly to neuronal death in Alzheimer's disease. Iron accumulation drives the Fenton reaction — generating hydroxyl radicals that cause oxidative damage to lipids, proteins and DNA — and promotes lipid peroxidation and ferroptosis — a form of iron-dependent cell death that is increasingly recognised as an important mechanism of neuronal death in Alzheimer's disease.

Research on ferroptosis modulators in Alzheimer's disease — exploring therapeutic strategies targeting iron-dependent lipid peroxidation — was the subject of a book chapter contributed by Dr. Nishant Kumar Rana — connecting his expertise in oxidative stress, iron metabolism and cancer biology to the emerging field of ferroptosis therapeutics in neurodegeneration.

Causes and Risk Factors

Age

Advancing age is the single greatest risk factor for Alzheimer's disease — with risk doubling approximately every 5 years after age 65.

Genetics

Familial Alzheimer's Disease — Early Onset

Approximately 5–10% of Alzheimer's disease cases are familial — caused by highly penetrant mutations in one of three genes:

APP (Amyloid Precursor Protein) — Mutations increase the production of amyloid-β or alter the ratio of Aβ42 to Aβ40 — promoting aggregation
PSEN1 (Presenilin 1) — Mutations in the catalytic subunit of gamma-secretase — the most common cause of familial Alzheimer's disease — causing disease onset typically in the 30s–50s
PSEN2 (Presenilin 2) — Mutations similar to PSEN1 — causing slightly later onset disease

These mutations cause early-onset Alzheimer's disease — typically developing before age 65 — and are inherited in an autosomal dominant manner — meaning that a single copy of the mutant gene is sufficient to cause disease.

APOE ε4 — The Major Genetic Risk Factor for Late-Onset Alzheimer's

The most important genetic risk factor for late-onset Alzheimer's disease (the far more common form, developing after age 65) is the APOE ε4 allele of the apolipoprotein E (APOE) gene. APOE ε4:

Increases Alzheimer's disease risk approximately 3-fold for heterozygous carriers (one ε4 allele) and approximately 12-fold for homozygous carriers (two ε4 alleles)
Accelerates amyloid-β accumulation and impairs its clearance
Is present in approximately 25% of the general population and 40–65% of Alzheimer's patients

Other Genetic Risk Factors

Genome-wide association studies (GWAS) have identified more than 70 genetic risk loci for late-onset Alzheimer's disease — including variants in genes involved in immune function (TREM2, CD33), lipid metabolism (CLU, ABCA7), endocytosis (BIN1, PICALM) and synaptic function — collectively painting a picture of Alzheimer's disease as a condition influenced by multiple biological pathways.

Down Syndrome

People with Down syndrome — who carry three copies of chromosome 21 (on which the APP gene resides) — produce excess amyloid-β throughout life and develop Alzheimer's disease pathology with near-universal penetrance — typically developing clinical symptoms in their 50s.

Cardiovascular and Metabolic Risk Factors

Several modifiable cardiovascular and metabolic risk factors are associated with increased Alzheimer's disease risk:

Hypertension — Particularly in midlife
Diabetes mellitus — Type 2 diabetes is associated with a 50–65% increased risk
Obesity — Particularly midlife obesity
Physical inactivity
Smoking
Excessive alcohol consumption
Depression
Social isolation and loneliness
Hearing loss
Air pollution
Low educational attainment

The Lancet Commission on Dementia Prevention (2020) identified 12 modifiable risk factors — collectively accounting for approximately 40% of dementia cases — suggesting that up to 40% of dementia cases could theoretically be prevented or delayed through risk factor modification.

Protective Factors

Higher educational attainment — Associated with greater cognitive reserve — enabling the brain to tolerate more Alzheimer's pathology before symptoms appear
Physical exercise — Particularly aerobic exercise — consistently associated with reduced dementia risk
Cognitive engagement — Lifelong intellectual stimulation — reading, music, social engagement
Mediterranean diet — Associated with reduced Alzheimer's risk
Social engagement and connection
Management of cardiovascular risk factors

Symptoms and Stages

Alzheimer's disease progresses through a characteristic sequence of stages — from preclinical disease (pathology present but no symptoms) through mild cognitive impairment to mild, moderate and severe dementia:

Preclinical Alzheimer's Disease

Amyloid plaques and neurofibrillary tangles begin to accumulate in the brain 15–20 years before the first clinical symptoms appear. During this long preclinical phase, the brain is undergoing progressive pathological change — but the person has no symptoms and performs normally on cognitive tests. Detecting and treating Alzheimer's disease during this preclinical phase — before irreversible neuronal loss has occurred — is the ultimate goal of early detection research.

Mild Cognitive Impairment (MCI)

The transition from preclinical disease to symptomatic disease is characterised by mild cognitive impairment (MCI) — a stage in which cognitive decline is noticeable to the person and those around them, but does not significantly impair daily functioning. Memory — particularly the ability to form new memories and recall recent events — is the most commonly affected domain. Approximately 10–15% of people with MCI progress to Alzheimer's dementia each year.

Mild Dementia

As the disease progresses, cognitive impairment becomes more significant — affecting daily functioning and requiring increasing support:

Memory loss — particularly for recent events — becomes more severe
Word-finding difficulties (anomia) and reduced vocabulary
Disorientation — particularly in unfamiliar environments
Difficulty with complex tasks — managing finances, planning and organisation
Personality and mood changes — withdrawal, depression, irritability
Getting lost in familiar places

Moderate Dementia

In moderate Alzheimer's disease, the person requires substantial assistance with daily activities:

Significant memory loss — including for personal history and the names and faces of family members
Confusion about time, place and identity
Increasing difficulty with language — both speaking and understanding
Behavioural and psychological symptoms — agitation, aggression, wandering, sleep disturbance, hallucinations and delusions
Loss of impulse control
Significant assistance needed with personal care — bathing, dressing, toileting

Severe Dementia

In the final stage of Alzheimer's disease, the person is entirely dependent on others for all aspects of care:

Near-complete loss of verbal communication
Inability to recognise family members
Complete dependence for all personal care
Loss of mobility — becoming bedbound
Dysphagia (difficulty swallowing) — leading to weight loss and aspiration pneumonia
Susceptibility to infections
Death — typically from complications of severe dementia including aspiration pneumonia, urinary tract infections and other infections

Diagnosis

Clinical Assessment

The diagnosis of Alzheimer's disease begins with a comprehensive clinical assessment — including:

Detailed history — From the patient and an informant (family member or carer) — characterising the onset, progression and pattern of cognitive symptoms
Cognitive testing — Using standardised instruments including the MMSE (Mini-Mental State Examination), MoCA (Montreal Cognitive Assessment) and neuropsychological test batteries
Neurological examination — Assessing for focal neurological signs that might suggest an alternative diagnosis
Psychiatric assessment — For depression, anxiety and psychotic symptoms

Biomarker Investigations

Advances in Alzheimer's disease biomarkers have transformed the diagnostic approach — enabling biological confirmation of the underlying Alzheimer's pathology:

Amyloid PET — Positron emission tomography imaging using amyloid-binding radiotracers (florbetapir, florbetaben, flutemetamol) — directly visualising amyloid plaques in the brain
Tau PET — PET imaging using tau-binding radiotracers — visualising neurofibrillary tangles and their distribution
CSF biomarkers — Lumbar puncture to measure amyloid-β42, total tau and phosphorylated tau in cerebrospinal fluid — reduced Aβ42 and elevated tau are characteristic of Alzheimer's disease
Blood-based biomarkers — A rapidly advancing field — with plasma phospho-tau 217 (p-tau217) emerging as a highly accurate blood-based biomarker of Alzheimer's disease — offering the prospect of simple, affordable diagnosis through a blood test
MRI — Brain MRI identifies the pattern of hippocampal and cortical atrophy characteristic of Alzheimer's disease and excludes structural causes of cognitive decline
FDG-PET — Fluorodeoxyglucose PET imaging reveals the characteristic pattern of reduced glucose metabolism in the temporal and parietal cortices in Alzheimer's disease

The AT(N) Framework

The AT(N) biomarker framework — developed by the National Institute on Aging and the Alzheimer's Association — classifies individuals according to their amyloid (A), tau (T) and neurodegeneration (N) biomarker status — enabling a biological definition of Alzheimer's disease independent of clinical symptoms — and a more precise characterisation of disease stage for research and clinical trials.

Treatment

Symptomatic Treatments

Acetylcholinesterase Inhibitors

The first class of drugs approved for Alzheimer's disease — targeting the cholinergic deficit (loss of acetylcholine-producing neurons) that is a characteristic feature of the disease:

Donepezil — Approved for mild, moderate and severe Alzheimer's disease — once-daily dosing — the most widely prescribed Alzheimer's medication
Rivastigmine — Available in oral and transdermal patch formulations — approved for mild to moderate Alzheimer's disease
Galantamine — Available in immediate-release and extended-release formulations — approved for mild to moderate Alzheimer's disease

These drugs modestly improve cognitive and functional symptoms in some patients — but do not slow the underlying disease progression.

Memantine

Memantine — an NMDA (N-methyl-D-aspartate) receptor antagonist — modulates glutamate neurotransmission — approved for moderate to severe Alzheimer's disease. It can be combined with acetylcholinesterase inhibitors for additional benefit.

Disease-Modifying Treatments

The most transformative recent development in Alzheimer's treatment is the approval of the first disease-modifying therapies — drugs that directly target the amyloid pathology and have been shown to meaningfully slow cognitive decline:

Lecanemab (Leqembi)

Lecanemab — a monoclonal antibody that selectively binds to and removes amyloid-β protofibrils — was approved by the FDA in January 2023 for early Alzheimer's disease (MCI and mild dementia). The Phase 3 CLARITY AD trial demonstrated a 27% slowing of cognitive decline over 18 months compared to placebo — the first drug to demonstrate a meaningful slowing of Alzheimer's progression in a large clinical trial.

Donanemab

Donanemab — a monoclonal antibody targeting a modified form of amyloid-β (pyroglutamate Aβ) present specifically in amyloid plaques — was approved by the FDA in July 2024 for early Alzheimer's disease. The Phase 3 TRAILBLAZER-ALZ 2 trial demonstrated a 35% slowing of cognitive decline in patients with low-to-intermediate tau pathology — and demonstrated that 40% of patients achieved complete amyloid clearance within 12 months.

Both drugs are associated with amyloid-related imaging abnormalities (ARIA) — including brain swelling and microhaemorrhages — which require careful monitoring.

Management of Behavioural and Psychological Symptoms

The behavioural and psychological symptoms of Alzheimer's disease — agitation, aggression, wandering, sleep disturbance, depression, anxiety, hallucinations and delusions — are among the most challenging aspects of the disease for patients, families and carers:

Non-pharmacological approaches — Including structured activity, music therapy, reminiscence therapy, bright light therapy and carer education — are the first-line approach
Antidepressants — For depression and anxiety — SSRIs (sertraline, citalopram) are preferred
Antipsychotics — For severe agitation or psychosis — used cautiously due to increased risk of stroke and death in elderly patients with dementia
Melatonin and sleep hygiene interventions — For sleep disturbance

Non-Pharmacological Approaches

Cognitive stimulation therapy — Structured group activities designed to stimulate cognitive function
Physical exercise — Aerobic exercise, strength training and balance exercise — with evidence of both symptomatic benefit and potential neuroprotective effects
Occupational therapy — Maintaining independence and function for as long as possible
Carer support and education — Essential for the wellbeing of both patients and their carers
Dietary approaches — Mediterranean diet, MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay)

Alzheimer's Disease in India

India faces a significant and growing Alzheimer's disease burden — with approximately 4 million people estimated to be living with Alzheimer's disease and other dementias — a number expected to more than double by 2050 as India's population ages. The burden of Alzheimer's disease in India is compounded by:

Low awareness — among the general public, primary care physicians and policymakers
Underdiagnosis — due to limited access to specialist neurological and geriatric care
Cultural attitudes — that may normalise cognitive decline as a normal part of ageing
Limited access to specialist services — particularly in rural areas
High carer burden — falling primarily on family members — particularly women — with limited formal support services
Rapidly ageing population — creating a growing tsunami of dementia that India's healthcare system must prepare for

The Dementia India Report — published by the Alzheimer's and Related Disorders Society of India (ARDSI) — has played an important role in raising awareness and advocating for a national dementia strategy. Research institutions including ICMR-funded institutes and India's leading academic medical centres are increasingly focusing on Alzheimer's disease — recognising it as one of the most important emerging public health challenges for India in the 21st century.

Research on ferroptosis modulators in Alzheimer's disease — including the book chapter contributed by Dr. Nishant Kumar Rana during his time as an ICMR Research Associate — represents an important Indian contribution to the global effort to develop new therapeutic strategies for this devastating disease.

Research Frontiers

Alzheimer's disease research is advancing on multiple fronts — with an unprecedented level of scientific activity and investment:

Anti-amyloid therapy — Following the approval of lecanemab and donanemab — the next generation of anti-amyloid antibodies and BACE1 inhibitors is in development
Anti-tau therapy — Tau-targeting antibodies and antisense oligonucleotides in clinical development
Neuroinflammation targeting — TREM2 agonists, microglial modulation and anti-inflammatory approaches
Ferroptosis and iron dysregulation — Targeting iron accumulation and lipid peroxidation as drivers of neuronal death
APOE4 targeting — Gene therapy and small molecule approaches targeting the major genetic risk factor
Synaptic protection — Approaches to preserve synaptic function and connectivity
Blood-based biomarkers — Development of accurate, affordable blood tests for early diagnosis
Digital biomarkers — Using smartphones, wearables and digital assessments for early detection and disease monitoring
Prevention trials — Testing interventions in cognitively normal individuals at high risk of developing Alzheimer's disease
Artificial intelligence — Using machine learning to identify new drug targets, predict disease progression and personalise treatment